Search results
Results from the WOW.Com Content Network
A multinational clinical trial investigating N-Acetyl-L-Leucine for the treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff) began in 2019 [14] Recruitment is ongoing. IntraBio is also conducting parallel clinical trials with N-Acetyl-L-Leucine for the treatment of Niemann-Pick disease type C [15] and Ataxia-Telangiectasia. [16]
Tay–Sachs disease is an inherited lysosomal storage disease that results in the destruction of nerve cells in the brain and spinal cord. [1] The most common form is infantile Tay–Sachs disease, which becomes apparent around the age of three to six months of age, with the baby losing the ability to turn over, sit, or crawl. [1]
N-Acetyl-L-Leucine is being studied for the treatment of GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases), [7] ataxia-telangiectasia, [8] Lewy body dementia, [9] amyotrophic lateral sclerosis, restless legs syndrome, multiple sclerosis, and migraine. [10]
Signs and symptoms of GM2-gangliosidosis, AB variant are identical with those of infantile Tay–Sachs disease, except that enzyme assay testing shows normal levels of hexosaminidase A. [2] Infantile Sandhoff disease has similar symptoms and prognosis, except that there is deficiency of both hexosaminidase A and hexosaminidase B. Infants with this disorder typically appear normal until the age ...
Out of 604 monitored pregnancies where there was a prenatal diagnosis of Tay–Sachs disease, 583 pregnancies were terminated. Of the 21 pregnancies that were not terminated, 20 of the infants went on to develop classic infantile Tay–Sachs disease, and the 21st case progressed later to adult-onset Tay–Sachs disease.
The main members of this group are Niemann–Pick disease, Fabry disease, Krabbe disease, Gaucher disease, Tay–Sachs disease and metachromatic leukodystrophy. They are generally inherited in an autosomal recessive fashion, but notably Fabry disease is X-linked recessive .
Tay–Sachs disease was the first of these disorders to be described, in 1881, followed by Gaucher disease in 1882. In the late 1950s and early 1960s, de Duve and colleagues, using cell fractionation techniques, cytological studies, and biochemical analyses, identified and characterized the lysosome as a cellular organelle responsible for ...
Although no cure for Tay–Sachs disease has been found, antenatal genetic screening has virtually eliminated the disease in the Ashkenazi Jewish population in both the United States and Israel. In 1979, Kaback served on the first National Institutes of Health (NIH) panel to recommend antenatal diagnosis in cases where a couple might be at risk ...